Loading...
Market
Retraction of other major hydroxychloroquine studies by end of 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Scientific journals and publications
Story
Didier Raoult's IHU Hydroxychloroquine Study Officially Retraction After Five-Year COVID-19 Controversy
Dec 17, 2024, 01:00 PM
The prominent study on hydroxychloroquine for COVID-19, led by Professor Didier Raoult and his team at the IHU Méditerranée Infection in Marseille, has been officially retracted. This research had been a cornerstone for proponents of the drug as a treatment against COVID-19. The retraction marks a significant development in the ongoing debate over the efficacy of hydroxychloroquine, which has faced scrutiny regarding its methodology and conclusions. The study, which had been defended by Raoult and his colleague Philippe Gautret, has been invalidated after nearly five years of controversy surrounding its claims. Critics have long argued that the study should have been retracted much earlier, reflecting the contentious nature of hydroxychloroquine's role in the pandemic response.
View original story
Similar markets
Study published without consequences • 25%
Study published with consequences for Dr. Olson-Kennedy • 25%
Study remains unpublished • 25%
Other outcome • 25%
Increased scrutiny on NIH studies • 25%
Changes in gender-affirming care policies • 25%
No significant consequence • 25%
Other consequence • 25%
Yes • 50%
No • 50%
Study published • 25%
NIH takes action • 25%
Congressional hearing held • 25%
No significant outcome • 25%
Acknowledge and propose further studies • 25%
Deny correlation and defend vaccine safety • 25%
Announce new vaccine formulations • 25%
No official response • 25%
